Powering the genetic medicine revolution
Our novel, synthetic DNA vector, “doggybone” or dbDNA™, and its enzymatic production, enable us to make DNA at the speed, scale and purity necessary to support the rapid growth of genetic medicines.
DNA made using enzymes
We are disrupting the decades-old technology of DNA production, moving away from restrictive biological approaches to instead use a synthetic DNA vector.Our platform technology
Enzymatic manufacturing enables multi-gram GMP DNA production in weeks rather than months
Manufactured using benchtop equipment with a significantly smaller footprint than fermentation-based production
dbDNA™ technology is highly portable and amenable to technology transfer
dbDNA™ can encode long, complex, unstable sequences, eliminates bacterial sequences, and has a strong expression profile
Addressing a broad market
Our versatile dbDNA™ technology is being applied across the genetic medicine industry.
What can we do for you?
We offer a range of services to support development and commercialisation of the next generation of DNA products.
- Catalogue products
- Molecular biology
- Custom research grade
- Toxicology materials
- GMP dbDNA™ (critical starting materials)
- GMP dbDNA™ (drug substance)
- Commercial supply / on-site supply
- Analytical development
- Scale up development
- Regulatory support
Headquartered in Hampton
Take a tour of our stunning buildings and state-of-the-art dbDNA™ manufacturing facilities.View our facilities
White Paper – The future of Industrial Scale Lentiviral Vector ManufacturingRead Article
Article – Antibiotics in biopharmaceutical productionRead Article
Webinar – Strategies for commercialising a novel enzymatic DNA technologyRead Article
Info sheet – Enzymatic DNA for mRNA productionDownload
Vaccines – SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal ModelRead Article
15 November 2022
Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform
Hampton, UK, 15 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene...
26 September 2022
Touchlight awarded Innovate UK grant for the measurement and intracellular visualisation of synthetic DNA constructs
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has been awarded an Innovate UK grant enabling it to work, alongside partners, at addressing the...
06 September 2022
Lonza and Touchlight collaborate on end-to-end mRNA offering
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNA). Touchlight provides synthetic DNA through a cell-free enzymatic process, with...
We'd like to hear from you
For more information on how our dbDNA™ technology could help advance your project, please contact us.Get in touch